The FDA Orange Book, officially titled Approved Drug Products with Therapeutic Equivalence Evaluations, serves as the definitive regulatory database for pharmaceutical products approved for safety and effectiveness under the Federal Food, Drug, and Cosmetic Act.
It provides all data on active ingredients, proprietary names, and applicant holders, while identifying Reference Listed Drugs (RLD) and Reference Standards (RS) essential for generic drug development. The service details Therapeutic Equivalence (TE) codes, which signify whether a generic product is bioequivalent to its brand-name counterpart, and maintains the official record of patent listings and regulatory exclusivity periods that dictate market competition timelines.
Important: we do not recommend the usage of this resource for personal medication.
Pharmaceutical scientists apply this data to identify generic entry opportunities by tracking patent expirations and exclusivity windows to guide R&D investment. Professionals in these fields typically use this resource to:
- Verify reference standards for bioequivalence testing protocols and formulation alignment.
- Strategically plan Abbreviated New Drug Application (ANDA) submissions based on Paragraph IV certifications.
- Monitor the patent landscape to mitigate infringement risks during manufacturing scale-up and lifecycle management.
